Reschke et al. reviewed experiences of rechallenging with checkpoint inhibitors in 570 melanoma patients [31], divided into four groups: (1) rechallenge with anti-PD-1 following disease progression in anti-PD-1 therapy; (2) rechallenge with anti-PD-1 and anti-CTLA-4 following disease progression in anti-PD-1 therapy; (3) rechallenge with anti-CLTA-4 following disease progression in anti-CTLA-4 therapy; and (4) rechallenge following toxicity-related treatment discontinuation. This evidence concerns the gene CTLA4 and melanoma.